Legal attitude: Art. 17 para. 1 MAR - confidential information. Br> Management Board of BLIRT S.A. (Issuer) informs that on January 3, 2018, he received a letter from the National Center for Research and Development (NCBR) regarding the project "Pre-clinical and clinical trials of a candidate for a drug in the treatment of invasive systemic fungal infections" (Project), rejection of the report on implementation the first stage of the Project as a result of a negative assessment of experts. Rejection of the report means that the expected end result of the first stage of the Project has not been achieved, which is consistent with the Issuer's opinion expressed in this report.
At the same time NCBR indicated that, in accordance with the recommendations of experts, further implementation of the Project is pointless and recommended that the Project be completed immediately. br> The Issuer informed in the current report ESPI No. 30/2017 of November 14, 2017 on the lack of competitive advantage in terms of therapeutic effectiveness of the compound being developed. br> Therefore, the Issuer will submit the documents required by the NCRD to settle the Project as part of the co-financing received. br>
Source: company website, investor relations, current and periodic reports.